Accuracy of Half of the Usual Radiotracer Dose in SPECT (SPECT-Light)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01412827
Recruitment Status : Completed
First Posted : August 9, 2011
Last Update Posted : February 24, 2016
Information provided by (Responsible Party):
Renee Hessian, Ottawa Heart Institute Research Corporation

Brief Summary:
There has been a shortage of nuclear isotopes, not only in Canada but around the world. New, more sensitive SPECT cameras can obtain better images in shorter scan times. These cameras have also shown the ability to use a smaller dose of radioisotope to obtain the images. New software has been tested on the standard camera, the GE Infinia-Hawkeye SPECT/CT. The Diagnostic Imaging Department of The University of Ottawa Heart Institute has also acquired a new camera, the Discovery NM530c CZT and has been doing heart scans in shorter times. The investigators will now be looking at the quality of images using less isotope during SPECT myocardial perfusion imaging for diagnostic and prognostic purposes.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Radiation: 1/2 dose of 99mTc OR 201Tl tracers Not Applicable

Detailed Description:

SPECT MPI is well accepted as a reliable and cost-effective tool for diagnosis, risk stratification and management of patients with suspected or known coronary artery disease (CAD) (1;2). MPI represents approximately 40% of nuclear medicine patient studies and most of these use 99mTc-sestamibi or 99mTc-tetrofosmin(3). Rest/stress MPI using 99mTc-sestamibi and 99mTc-tetrofosmin uses more tracer doses than many other nuclear medicine tests and thus account for >50% of injected radiotracer activity(3). Thus, interruptions in the supply of 99Mo, the parent isotope of 99mTc, significantly affect stress MPI imaging and associated patient care.

Alternatives to 99mTc-sestamibi and 99mTc-tetrofosmin for perfusion imaging include 201Tl for SPECT imaging and 82Rb or 13NH3 for positron emission tomography (PET) imaging (4;5). MPI using 201Tl has similar diagnostic accuracy but image interpretation is more difficult due to greater scatter and attenuation. Moreover, the patient effective radiation dose for MPI using a standard injected dose of 3.5mCi of 201Tl is ~20 mSv. This radiation dose is twice that of 99mTc tracers which typically deliver an effective dose of ~10 mSv. PET imaging with 82Rb or 13NH3 is another alternative, but is much more expensive and not routinely available in Canada due to a very limited install base of PET scanners and associated cyclotrons. The number of SPECT cameras operational in Canada is more than 40 times the number of PET scanners.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Diagnostic and Prognostic Accuracy of Stress SPECT Myocardial Perfusion Imaging With Half the Usual Radiotracer Dose
Study Start Date : April 2010
Actual Primary Completion Date : March 2013
Actual Study Completion Date : September 2014

Arm Intervention/treatment
Comparison of radioisotope dosing Radiation: 1/2 dose of 99mTc OR 201Tl tracers

Rest: Imaging will occur 30 to 60 minutes after injection of tracer.

Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer.

Primary Outcome Measures :
  1. Rate of non-fatal infarction or death in the normal group of SPECT-Light acquisitions versus standard SPECT acquisitions [ Time Frame: 2 years ]
    The difference in the rate of non-fatal infarction or death that occurs in the normal group of the combined SPECT-Light acquisition protocols (LDa and LDb) versus the outcome that occurs in the acquisitions obtained by the standard SPECT (FD) protocol.

Secondary Outcome Measures :
  1. Comparison of classification of the degree of abnormality based on the two image acquisition protocols [ Time Frame: 2 years ]

    A comparison of classification of the degree of abnormality based on the two image acquisition protocols. Multi-level correlation between the two image sets (LDa vs 2 and LDb vs 2) will be obtained against the standard SPECT (FD) images.

    The combined rates of non-fatal MI or death in each of the LD images as well as the standard dose images (FD) which are considered abnormal (SSS ≥ 4) will also be calculated.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Consecutive patients presenting for clinically indicated SPECT perfusion scan
  • Patients presenting to sites with a functional CZT camera. Available sites are Ottawa (OHI), Mississauga, and Calgary.
  • Age >18 years old

Exclusion Criteria:

  • Patients with a life expectancy less than 1 year, from non cardiac cause
  • Age < 18 years old or lack of consent
  • Allergy or contraindication to dipyridamole
  • Refractory angina or infarction or need for urgent angiography
  • Known pregnancy
  • Uncontrolled atrial fibrillation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01412827

Canada, Ontario
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
Sponsors and Collaborators
Ottawa Heart Institute Research Corporation
Principal Investigator: Renée Hessian, MD Ottawa Heart Institute Research Corporation


Responsible Party: Renee Hessian, Dr. Renee Hessian, Ottawa Heart Institute Research Corporation Identifier: NCT01412827     History of Changes
Other Study ID Numbers: HI Protocol #2010127-01H
First Posted: August 9, 2011    Key Record Dates
Last Update Posted: February 24, 2016
Last Verified: February 2016

Keywords provided by Renee Hessian, Ottawa Heart Institute Research Corporation:
Single-photon emission computed tomography
myocardial perfusion imaging
cadmium zinc telluride

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases